Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population LevelsThomas M. Snyder, Harlan Robins, James R. Heath et al.|medRxiv|2020Cited by 234
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Alberto Borghetti, Emanuele Focà et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trialFrancesca Lombardi, Simone Belmonti, Eugenia Quirós-Roldán et al.|Journal of Antimicrobial Chemotherapy|2017Cited by 31
Timed Short Messaging Service Improves Adherence and Virological Outcomes in HIV-1–Infected Patients With Suboptimal Adherence to Antiretroviral TherapyAdriana Ammassari, Andrea Antinori, Maria Paola Trotta et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2011Cited by 25